Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Needa Brown"'
Publikováno v:
Cancer Nanotechnology, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) d
Externí odkaz:
https://doaj.org/article/bcb38076fd6e4bebba02ff716de87352
Autor:
Shicheng Yang, Allen Green, Needa Brown, Alexis Robinson, Merline Senat, Bryanna Testino, Daniela M. Dinulescu, Srinivas Sridhar
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundOvarian cancer has long been known to be the deadliest cancer associated with the female reproductive system. More than 15% of ovarian cancer patients have a defective BRCA-mediated homologous recombination repair pathway that can be therap
Externí odkaz:
https://doaj.org/article/f5390538ca7041c58b0cd2c636d4b19b
Autor:
Shicheng Yang, Needa Brown, Abigail L. Campbell, Kushi Aggarwal, Daniela M. Dinulescu, Srinivas Sridhar
Publikováno v:
Cancer Research. 83:1994-1994
Ovarian cancer has long been known to be the deadliest cancer associated with the female reproductive system. More than 15% of ovarian cancer patients have a defective BRCA-mediated homologous recombination repair pathway that can be therapeutically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cbf962d8fc558b20f04898afacdd8fd
https://doi.org/10.1158/1538-7445.am2023-1994
https://doi.org/10.1158/1538-7445.am2023-1994